Economic information and modeling report
Modeling overview
35 evidence topics · 14 sources
Summary
The published economic evaluations of HAE prophylaxis collected for this report date from 2018 to 2026, and none evaluates onvuzosiran.
The 2018 ICER final evidence report compared Cinryze, Haegarda, and lanadelumab with no prophylaxis in a Markov model with one-month cycles over a lifetime horizon, from a US health care system perspective with a 3% discount rate. The modeled population had a mean age of 39.6 years, was 68.4% female, and had a baseline rate of 3.39 attacks per month. Against no prophylaxis, the incremental cost-effectiveness ratios were $5,954,000 for Cinryze, $328,000 for Haegarda, and $1,108,000 for lanadelumab, with 0.75, 1.19, and 1.19 QALYs gained. The report concluded that, at the drug prices of 2018, prophylactic treatment “does not meet traditional cost-effectiveness thresholds” in its base case, and that sensitivity analyses produced widely varying findings. Its budget impact analysis of lanadelumab used an annual WAC of $565,557, covered five years without discounting, and reached 13% of the $991 million threshold at WAC.
ICER's 2021 observational real-world evidence update reported incremental costs per QALY gained of $30,070,000 for Cinryze, $13,430,000 for Haegarda, and $12,370,000 for Takhzyro, and states that incremental ratios “can become extreme with small denominators”.
The 2026 NICE draft guidance for England does not recommend donidalorsen. It rests on a company cost-comparison analysis that assumed equal efficacy across long-term prophylactic treatments, and states that the most likely cost-effectiveness estimates for donidalorsen cannot be determined.
The 2018 ICER analysis evaluated the three drugs then approved for long-term prophylaxis of HAE-1/2 (Cinryze, Haegarda, and lanadelumab), and the 2021 ICER update reports results for the same three drugs. No US cost-effectiveness or budget impact analysis of berotralstat, garadacimab, or donidalorsen was identified.
Comparator economic assessment: reference strategy
Comparator-treatment economic assessment: observational real-world evidence update
Comparator economic assessment: interpretation of incremental ratios
Comparator cost-effectiveness model: structure
Comparator cost-effectiveness model: base-case incremental results versus no prophylaxis
| Measure | Cinryze | Haegarda | Lanadelumab |
|---|---|---|---|
| QALYs gained | “0.75” | “1.19” | “1.19” |
| Attacks avoided | “860” | “1,430” | “1,480” |
| Incremental cost-effectiveness ratio, US health system perspective | “$5,954,000” | “$328,000” | “$1,108,000” |
| Cost per attack avoided, US health system perspective | “$5,168” | “$273” | “$892” |
Comparator cost-effectiveness model: conclusion
Comparator budget impact analysis: lanadelumab per-patient results
| Average annual per-patient budget impact | At WAC | At net price |
|---|---|---|
| Lanadelumab | “$620,338” | “$478,464” |
| Haegarda/Cinryze/no long-term prophylaxis (49%/49%/2%) | “$524,192” | “$524,192” |
| Difference | “$96,145” | “-$45,729” |
Comparator budget impact analysis: population results and threshold
Comparator budget impact analysis: switch from no prophylaxis scenario
Health technology assessment of the same-target antisense comparator: England
Sponsor statement on hereditary angioedema market size
Budget impact framework for a new long-term prophylactic agent
Displaced comparator mix
Time horizon and discounting of a published budget impact analysis
US prevalence and the population eligible for long-term prophylaxis
US diagnosed prevalence from claims data
“For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
US population with C1 inhibitor deficiency and prophylaxis use in a patient survey
“Hereditary angioedema (HAE) caused by C1 inhibitor (C1-INH) deficiency is a rare, debilitating, and potentially fatal genetic disorder that affects <8000 people in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 737 patients included in the final analysis, 37.3% (n = 275) were prescribed and using on-demand–only treatment and reported treating 67.2% of their HAE attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 62.7% (n = 462) who received prophylactic treatment in addition to having on-demand treatment available, 32.3% (n = 149) received one of the novel SC prophylactic therapies (C1-INH [SC] or lanadelumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Share of US patients treated with long-term prophylaxis and the agents initiated
“In the United States, approximately 70% of patients with HAE are treated with LTP, primarily non-androgens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients on LTP, 42% (138/328) initiated Takhzyro (lanadelumab), 30% (97/328) initiated Haegarda (C1 esterase inhibitor [human]), 17% (54/328) initiated Cinryze (C1 esterase inhibitor [human]), and 12% (39/328) initiated Orladeyo (berotralstat) as the index LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Onvuzosiran dosing interval in development
Wholesale acquisition cost of donidalorsen per pen and per year at every 8 weeks
Estimated annual wholesale acquisition cost of long-term prophylactic agents
| Product | Estimated annual WAC |
|---|---|
| Dawnzera (donidalorsen), every 4 weeks | “$747,006” |
| Andembry (garadacimab) | “$685,200” |
| Orladeyo (berotralstat) | “$579,885” |
| Takhzyro (lanadelumab) | “$685,171” |
| Haegarda (C1 esterase inhibitor, subcutaneous) | “$604,152” |
| Cinryze (C1 esterase inhibitor, intravenous) | “$665,224” |
Wholesale acquisition cost of oral on-demand sebetralstat
Medicare Part B payment limits for physician-administered agents, fourth quarter of 2026
| Product | HCPCS code | Short description | Dosage unit | Payment limit ($) |
|---|---|---|---|---|
| Lanadelumab (Takhzyro) | “J0593” | “Inj., lanadelumab-flyo, 1 mg” | “1 mg” | “88.340” |
| C1 esterase inhibitor, intravenous (Cinryze) | “J0598” | “C-1 esterase, cinryze” | “10 UNITS” | “67.065” |
| C1 esterase inhibitor, on-demand (Berinert) | “J0597” | “C-1 esterase, berinert” | “10 UNITS” | “79.329” |
| Recombinant C1 esterase inhibitor, on-demand (Ruconest) | “J0596” | “Injection, ruconest” | “10 UNITS” | “37.810” |
| Ecallantide, on-demand (Kalbitor) | “J1290” | “Ecallantide injection” | “1 MG” | “599.616” |
Federal Supply Schedule and Big Four prices, November 2026
Medicare Part D spending on long-term prophylactic agents, 2024
| Brand | Total spending, 2024 ($) | Beneficiaries, 2024 | Average spending per dosage unit, 2024 ($) | Average spending per beneficiary, 2024 ($) |
|---|---|---|---|---|
| Takhzyro (lanadelumab) | “223004902.8” | “512” | “12775.306747” | “435556.45078” |
| Orladeyo (berotralstat) | “77894702.6” | “221” | “1516.0510432” | “352464.71765” |
| Haegarda (C1 esterase inhibitor) | “82014748.23” | “187” | “2952.876629” | “438581.54134” |
| Cinryze (C1 esterase inhibitor) | “33104776.46” | “46” | “3256.1007633” | “719669.05348” |
Medicare Part D spending on on-demand agents, 2024
| Brand | Total spending, 2024 ($) | Beneficiaries, 2024 | Average spending per dosage unit, 2024 ($) | Average spending per beneficiary, 2024 ($) |
|---|---|---|---|---|
| Firazyr (icatibant) | “43713828.6” | “170” | “3553.9698049” | “257140.16824” |
| Icatibant (generic) | “32477428.42” | “658” | “955.46002803” | “49357.793951” |
| Berinert (C1 esterase inhibitor) | “34597556.94” | “63” | “3904.4754475” | “549167.57048” |
| Ruconest (recombinant C1 esterase inhibitor) | “55710878.24” | “128” | “7557.0914596” | “435241.23625” |
| Kalbitor (ecallantide) | “20871584.35” | “36” | “5624.2480059” | “579766.23194” |
Annual prices of lanadelumab used in a published budget impact analysis
Annual healthcare cost components before and after starting long-term prophylaxis: US commercial claims
| Cost component, per patient per year | Pre-index | Post-index |
|---|---|---|
| Medical costs, emergency room and inpatient | “$23,060”View highlighted excerpt for this quote | “$14,716”View highlighted excerpt for this quote |
| Medical costs, outpatient, home health, and other | “$2255”View highlighted excerpt for this quote | “$1668”View highlighted excerpt for this quote |
| Pharmacy costs, on-demand | “$217,857”View highlighted excerpt for this quote | “$167,462”View highlighted excerpt for this quote |
| Pharmacy costs, other | “$14,214”View highlighted excerpt for this quote | “$4193”View highlighted excerpt for this quote |
| Pharmacy costs, long-term prophylaxis | “$0”View highlighted excerpt for this quote | “$395,845”View highlighted excerpt for this quote |
| Total healthcare costs | “$165,348”View highlighted excerpt for this quote | “$515,333”View highlighted excerpt for this quote |